Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GaM-GBM Black African Phase 1 Study
PACTR202509858954027Phase 1Not yet recruiting
- Sponsor
- Stillpoint Ltd
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium maltolate in glioblastoma (GBM), sponsored by Stillpoint Ltd. Primary endpoints: Safety and tolerability and Maximum tolerated dose. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
gallium maltolate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on PACTR202509858954027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509858954027.